Crossmark

A pilot double-blind, placebo-controlled, randomized clinical trial of MitoQ in the treatment of septic shock: evaluating its effects on clinical outcomes and oxidative stress biomarker

Crossref DOI link: https://doi.org/10.1007/s00210-025-04526-9

Published Online: 2025-08-18

Published Print: 2026-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Moradbaki, Hadis

Hassani-Pajooh, Hanieh

Valizade-Hasanloei, Mohammad-Amin

Hatamkhani, Shima

Amini, Kiumarth

Zamanirafe, Maryam

Mehrpooya, Maryam

Taher, Abbas
License Information

Text and Data Mining valid from 2025-08-18

Version of Record valid from 2025-08-18
More Information

Article History

Received: 12 July 2025

Accepted: 5 August 2025

First Online: 18 August 2025

Declarations

:

: This study was approved by the Ethics Committee of Hamadan University of Medical Sciences (IR.UMSHA.REC.1402.688) and conducted in accordance with the 2013 Declaration of Helsinki. Written informed consent was obtained from all participants or their legal representatives before enrollment, in compliance with ethical guidelines.

: Since the study does not contain any information that could identify individual participants, consent for publication is not required for this work.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below